

Juanjuan Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2334265/publications.pdf>

Version: 2024-02-01

38
papers

1,532
citations

394421

19
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

2963
citing authors

#	ARTICLE	IF	CITATIONS
1	Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. <i>Diabetologia</i> , 2020, 63, 2102-2111.	6.3	259
2	Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation. <i>Frontiers in Immunology</i> , 2019, 10, 1998.	4.8	153
3	Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	143
4	The ACE2/Angiotensin-(1 α 7)/Mas Receptor Axis: Pleiotropic Roles in Cancer. <i>Frontiers in Physiology</i> , 2017, 8, 276.	2.8	87
5	Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 735-750.	6.4	75
6	Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis. <i>Cancer Biomarkers</i> , 2016, 16, 415-423.	1.7	71
7	Smoking Induced Extracellular Vesicles Release and Their Distinct Properties in Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2019, 10, 3435-3443.	2.5	57
8	Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. <i>EBioMedicine</i> , 2021, 67, 103365.	6.1	57
9	Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer. <i>Genomics</i> , 2020, 112, 2063-2071.	2.9	55
10	Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. <i>Critical Care</i> , 2020, 24, 438.	5.8	54
11	The Role of Interleukin-17 in Lung Cancer. <i>Mediators of Inflammation</i> , 2016, 2016, 1-6.	3.0	45
12	Metabolic characteristics of large and small extracellular vesicles from pleural effusion reveal biomarker candidates for the diagnosis of tuberculosis and malignancy. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1790158.	12.2	39
13	Plasma Metabolomic Profiling of Patients Recovered From Coronavirus Disease 2019 (COVID-19) With Pulmonary Sequelae 3 Months After Discharge. <i>Clinical Infectious Diseases</i> , 2021, 73, 2228-2239.	5.8	39
14	Retinoic Acid Receptor-Related Orphan Receptors: Critical Roles in Tumorigenesis. <i>Frontiers in Immunology</i> , 2018, 9, 1187.	4.8	38
15	The multifaceted roles of FOXM1 in pulmonary disease. <i>Cell Communication and Signaling</i> , 2019, 17, 35.	6.5	34
16	Identification of the Prognostic Significance of Somatic Mutation-Derived LncRNA Signatures of Genomic Instability in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 657667.	3.7	31
17	Inflammatory Profiles and Clinical Features of Coronavirus 2019 Survivors 3 Months After Discharge in Wuhan, China. <i>Journal of Infectious Diseases</i> , 2021, 224, 1473-1488.	4.0	30
18	Development and validation of a novel scoring system developed from a nomogram to identify malignant pleural effusion. <i>EBioMedicine</i> , 2020, 58, 102924.	6.1	26

#	ARTICLE	IF	CITATIONS
19	Proteomics of extracellular vesicles in plasma reveals the characteristics and residual traces of COVID-19 patients without underlying diseases after 3 months of recovery. <i>Cell Death and Disease</i> , 2021, 12, 541.	6.3	25
20	Plasma Metabolomic Profiles in Recovered COVID-19 Patients without Previous Underlying Diseases 3 Months After Discharge. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4485-4501.	3.5	22
21	Immunoregulatory Roles of Extracellular Vesicles and Associated Therapeutic Applications in Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 2024.	4.8	21
22	An Integrative Transcriptomic and Metabolomic Study Revealed That Melatonin Plays a Protective Role in Chronic Lung Inflammation by Reducing Necroptosis. <i>Frontiers in Immunology</i> , 2021, 12, 668002.	4.8	20
23	Electroacupuncture Regulates Apoptosis/Proliferation of Intramuscular Interstitial Cells of Cajal and Restores Colonic Motility in Diabetic Constipation Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-10.	1.2	19
24	IL-17 induces EMT via Stat3 in lung adenocarcinoma. <i>American Journal of Cancer Research</i> , 2016, 6, 440-51.	1.4	19
25	Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity. <i>Frontiers in Medicine</i> , 2021, 8, 682087.	2.6	16
26	Airway Fusobacterium is Associated with Poor Response to Immunotherapy in Lung Cancer. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 201-213.	2.0	16
27	Characteristics of mental health implications and plasma metabolomics in patients recently recovered from COVID-19. <i>Translational Psychiatry</i> , 2021, 11, 307.	4.8	15
28	Comparison of clinical characteristics among younger and elderly deceased patients with COVID-19: a retrospective study. <i>Aging</i> , 2021, 13, 16-26.	3.1	14
29	Identification of robust genetic signatures associated with lipopolysaccharide-induced acute lung injury onset and astaxanthin therapeutic effects by integrative analysis of RNA sequencing data and GEO datasets. <i>Aging</i> , 2020, 12, 18716-18740.	3.1	10
30	The role of adrenergic receptors in lung cancer. <i>American Journal of Cancer Research</i> , 2018, 8, 2227-2237.	1.4	9
31	Changes in glomerular filtration rate and metabolomic differences in severely ill coronavirus disease survivors 3 months after discharge. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166289.	3.8	8
32	POU6F1 cooperates with RORA to suppress the proliferation of lung adenocarcinoma by downregulating HIF1A signaling pathway. <i>Cell Death and Disease</i> , 2022, 13, 427.	6.3	6
33	Evidence that dysplasia related microRNAs in Barrett's esophagus target PD-L1 expression and contribute to the development of esophageal adenocarcinoma. <i>Aging</i> , 2020, 12, 17062-17078.	3.1	5
34	The Correlation Between Clinical Features and Viral RNA Shedding in Outpatients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa331.	0.9	4
35	Comprehensive genomic and prognostic analysis of the IL-17 family genes in lung cancer. <i>Molecular Medicine Reports</i> , 2019, 19, 4906-4918.	2.4	3
36	Clinical characteristics and outcomes of severe or critical COVID-19 patients presenting no respiratory symptoms or fever at onset. <i>Engineering</i> , 2020, 7, 1452-1458.	6.7	3

#	ARTICLE	IF	CITATIONS
37	Reactive Oxygen Species-Mediated Cezanne Inactivation by Oxidation of its Catalytic Cysteine Residue in Hepatocellular Carcinoma. <i>Oncology Research</i> , 2019, 27, 1069-1077.	1.5	2
38	Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 673567.	2.8	2